News

AddToAny

Google+ Facebook Twitter Twitter

Diagnosis of Liposarcomas

Researchers have leveraged the latest advances in RNA technology and machine learning methods to develop a gene panel test that allows for highly accurate diagnosis of the most common types of liposarcoma.

It is claimed that the test quickly and reliably distinguishes benign lipomas from liposarcomas and can be performed in laboratories at a lower cost than current “gold standard” tests. The new NanoString assay is described in The Journal 
of Molecular Diagnosis
. Lead investigator Torsten Owen Nielsen said: “Many liposarcomas look like their benign and relatively common counterparts, lipomas. Diagnostic delay and uncertainty cause severe stress for patients, and misdiagnosis can have many consequences including delayed or inadequate treatment or unnecessary surgical procedures and long-term postoperative follow up.”

The retrospective and prospective cases probed by the NanoString assay had a 93% success rate and agreed with standard tests 97.8% of the time.  

bit.ly/3p1ui4W

Image Credit | Shutterstock

Related Articles

Diagnose crohn’s with an engineered organism

Researchers have engineered a bacterium with the necessary capabilities for diagnosing a human disease.

Genomic medicine: Coming to the clinic near you?

Dr Rameen Shakur takes a look at how biomedical science and genomics are playing a part in real-world clinical cardiology.

Unintended consequences

Computational biologist Gregorio Alanis- Lobato highlights the need for greater awareness of and further research into the effects of CRISPR-Cas9 genome editing.

The evolution of quality assessment

In 2011, UK NEQAS Cellular Pathology Technique (CPT) carried out tests across four schemes – it now covers 12 schemes with two in the pipeline. We hear from Chantell Hodgson, UK NEQAS CPT Scheme Manager.

Top